XML 47 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Quarterly Financial Information (Unaudited)
 12 Months Ended
Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]  
Quarterly Financial Information (Unaudited)
Quarterly Financial Information (Unaudited)
The following information has been derived from unaudited consolidated statements that, in the opinion of management, include all recurring adjustments necessary for a fair statement of such information.
 
Three Months Ended
 
March 31,
2017
 
June 30,
2017
 
September 30,
2017
 
December 31, 2017 (1)
Total revenues
$
53,504

 
$
54,433

 
$
46,016

 
$
77,028

Operating loss
(31,381
)
 
(35,270
)
 
(44,747
)
 
(26,492
)
Net loss
(32,377
)
 
(19,662
)
 
(40,836
)
 
(33,945
)
Net loss attributable to Intrexon
(31,399
)
 
(18,664
)
 
(39,689
)
 
(27,266
)
Net loss attributable to Intrexon per share, basic and diluted
$
(0.26
)
 
$
(0.16
)
 
$
(0.33
)
 
$
(0.23
)
 
Three Months Ended
 
March 31,
2016
 
June 30,
2016
 
September 30,
2016
 
December 31,
2016
Total revenues
$
43,438

 
$
52,501

 
$
48,985

 
$
46,002

Operating loss
(40,533
)
 
(23,222
)
 
(28,821
)
 
(32,590
)
Net loss
(65,320
)
 
(50,031
)
 
(30,011
)
 
(44,912
)
Net loss attributable to Intrexon
(64,429
)
 
(49,064
)
 
(28,982
)
 
(44,137
)
Net loss attributable to Intrexon per share, basic and diluted
$
(0.55
)
 
$
(0.42
)
 
$
(0.24
)
 
$
(0.37
)

(1)
During the fourth quarter of 2017, the Company recognized the remaining balance of deferred revenue associated with ZIOPHARM ECC2 upon the parties' mutual agreement to terminate (Note 5). The Company also recorded goodwill impairment charges primarily related to the AquaBounty reporting unit and an impairment charge related to certain of its in-process research and development assets (Note 11).